Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder characterized by genetic susceptibility, epidermal barrier dysfunction, and immune dysregulation. This review systematically expounds and analyzes the intricate cellular interactions between immune cells and keratinocytes (KCs) and their central roles in AD pathogenesis. The analysis emphasizes bidirectional crosstalk among diverse immune populations, such as Th2, Th17, regulatory T, and cytotoxic T cells, dendritic cells, and macrophages, mediated by cytokines, chemokines, and surface molecules, as well as how this cellular communication orchestrates key disease features, including inflammation, barrier breakdown, and chronic itch. Key signaling pathways, such as the JAK-STAT, NF-κB, and MAPK pathways, along with molecular targets including thymic stromal lymphopoietin, interleukin-4 receptor alpha subunit (IL-4Rα), OX40/OX40 ligand, protease-activated receptor 2, transient receptor potential vanilloid channels, and aryl hydrocarbon receptor, are critically evaluated for their contributions to disease mechanisms. The review also surveys current and emerging therapeutic approaches, ranging from biologics targeting IL-4Rα/IL-13 and small-molecule inhibitors to combination regimens and novel strategies involving microbiome modulation and gene editing. Future investigations should advance personalized medicine paradigms to improve the long-term control and management of AD.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: